I agree. New here, this article makes me feel great about the potential here. I thought that it would just be a trade....I am going long baby
Thank you for the link.....just read it. I am adding more tomorrow
I just read it....I expect much higher prices in July
finally some decent and informational posts
it happens all the time
Thank you very much for the educational posts!
I apologize for my ignorance. What is a poison pill and how it relates to GIG? Thank you!
CEO Ball will lie again like he did at Nedham.
He will say that everything is peachy that cash burn in getting better ( I guess to him better mean higher), he will reiterate previous higher guidance, he will say that they will respond to the FDA in a few more weeks, he will say that their metals part was a problem before but they did not find out how bad it was until now. He will say that the Brazilian opportunity is great and that he needs to spend the carnival in Rio with his puppet Ty Lombardi.....He will say that they are working on non-dilutive financing opportunities with Magna again who will again tell them and the shareholder bend over....here come another round of massive dilution.
After that Nedham will raise the target to $3....just because.
OK.....there was your preview.
I will take $1000 a share and become President of The Dreamer's Club.
In one more quarter they will be looking for more money because they will be close to the $9 million loan covenant. At this rate they will end up with 300 million shares in a year
I expect at least 75c in June and go from there
Needham & Company analyst Mike Matson lowered his price target on Amedica Corporation (NASDAQ: AMDA) to $1.00 (from $3.00) but maintained a Buy rating following disappointing Q1 results.
Matson commented, "AMDA's 1Q15 revenue and EPS were below consensus. Revenue declined 18% Y/Y and 8% sequentially as silicon nitride (SiN) implant sales growth slowed to 7%. AMDA lowered its 2015 revenue guidance to $19-20M from $23-24M (vs. consensus of $23.3M) with SiN growth of 15-20% (vs. 30-40% previously). We expect the composite cervical spacers to be cleared by the FDA later this year and to serve as a growth driver, and we also expect additional private label and/or OEM agreements (AMDA expects four additional agreements this year) to serve as catalysts and to drive revenue growth."
I give it a 90 - 95% chance of approval. If the FDA did not like the 510(k) they would have told them already. Only questions are regulatory and clarifications. CASCADE study was very rigorous and met all FDA criteria